KenTakeshitaMD

Physician

Dr. Takeshita is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
Yale-New Haven Medical CenterResidency, Internal Medicine, 1984 - 1986
Yale School of MedicineClass of 1983

PubMed

1 citations
A Case Report of Bacterial Meningitis Caused by an Emerging Strain of Penicillin-Resistant Non-Vaccine Serotype 10A.
Sonoko Minato, Michiko Yoshida, Kensuke Shoji, Nobuyuki Yotani, Kenichi Takeshita
Japanese Journal of Infectious Diseases. 2021-01-29
38 citations
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
Shinsuke Iida, Takaaki Chou, Shinichiro Okamoto, Hirokazu Nagai, Kiyohiko Hatake
International Journal of Hematology. 2010-06-18
204 citations
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Thomas E. Witzig, Peter H. Wiernik, Timothy E. Moore, Craig B. Reeder, Craig Cole
Journal of Clinical Oncology. 2009-11-10

Datopotamab Deruxtecan Granted Priority Review in the U.S. For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerJanuary 13th, 2025
Datopotamab Deruxtecan Granted Priority Review in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerJanuary 13th, 2025
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerDecember 9th, 2024
Join now to see all